Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
The aim of this study was to assess the efficacy, safety and tolerability of the antiepileptic compound levetiracetam (LEV) for the treatment of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD). We thus performed a randomized, double-blind, placebo-controlled, parallel-group pilot study in PD patients with moderate-to-severe LID on stable dopaminergic therapy. Placebo or LEV was administered twice daily (titrated from 250 to 2,000 mg/day) as add-on therapy. Subjects underwent evaluation of the unified-PD-rating scale (UPDRS) and the modified abnormal involuntary movement scale (AIMS). The primary outcome variable was the change of the AIMS score between baseline and end-of-treatment visit. Secondary variables included total UPDRS score and response to levodopa challenge. Of 32 randomized patients (mean age 65.2 years, 62.5% women), 17 received LEV and 15 placebo. After 11 weeks of treatment, mean changes of the modified AIMS from baseline were -1.5 (-26%) for LEV (p = 0.332) and +0.9 (+13%) for placebo (p = 0.588) without significant differences between groups. Mean changes of the UPDRS item 32/33 sum score from baseline showed significant improvement of dyskinesia in the LEV group [-1.0 (-20%); p = 0.012], but not in the placebo group [-0.4 (-8%); p = 0.306]. Treatment had no effects on UPDRS motor score or levodopa response. Frequency and quality of adverse events were similar in both treatment groups. Together, LEV showed only mild antidyskinetic effects without worsening of Parkinsonian symptoms or compromising levodopa efficacy. LEV was well tolerated in doses up to 2,000 mg/day. Further large controlled studies are warranted to evaluate the impact of LEV on LID in PD patients.
Wolz
Martin
M
Department of Neurology, Dresden University of Technology, Fetscherstraße 74, 01307 Dresden, Germany.
Löhle
Matthias
M
Strecker
Karl
K
Schwanebeck
Uta
U
Schneider
Christine
C
Reichmann
Heinz
H
Grählert
Xina
X
Schwarz
Johannes
J
Storch
Alexander
A
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects*; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010865:Pilot Projects; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D007980:Levodopa
Mov Disord. 2007 Jan 15;22(2):179-86
17094088
J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):295-7
14742609
J Neurol Neurosurg Psychiatry. 1998 May;64(5):573-6
9598668
Clin Neuropharmacol. 1983;6 Suppl 1:S35-51
6139165
Mov Disord. 2005 Feb;20(2):151-7
15390035
Neuroreport. 2003 Jul 1;14(9):1273-6
12824774
Curr Opin Investig Drugs. 2008 Jan;9(1):101-7
18183537
J Clin Psychiatry. 2008 Apr;69(4):546-54
18312060
Mov Disord. 2005 Mar;20(3):342-4
15580606
Epilepsia. 2001;42 Suppl 4:13-8
11564119
Ann Neurol. 2004 Jun;55(6):871-5
15174022
Eur J Pharmacol. 2008 Dec 28;601(1-3):99-102
19014930
Neurology. 2000 Sep 26;55(6):795-9
10993998
Curr Med Res Opin. 2004 Jan;20(1):115-20
14741081
Brain. 2001 Mar;124(Pt 3):546-57
11222455
Parkinsonism Relat Disord. 2005 Aug;11(5):333-4
15949966
Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S3-8
19131039
Lancet Neurol. 2005 Jun;4(6):366-70
15907741
Eur J Neurol. 2005 Dec;12(12):956-63
16324089
Acta Neurol Scand. 2006 Jan;113(1):18-24
16367894
Mov Disord. 2005 Jun;20(6):714-8
15704204
Eur J Pharmacol. 2004 Feb 6;485(1-3):159-64
14757136
Respiration. 1999;66(5):440-7
10516541
Neurology. 1998 May;50(5):1323-6
9595981
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
1564476
Pharmacol Res. 2000 Oct;42(4):281-5
10987984
Acta Neurol Scand. 2002 Apr;105(4):245-55
11939936
Ann Neurol. 2000 Apr;47(4 Suppl 1):S131-40
10762140
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6
15210974
J Neurosci. 2002 Sep 15;22(18):7850-5
12223537
Neurology. 1998 Jul;51(1):203-6
9674803
Neurology. 2004 Feb 10;62(3):381-8
14872017
Pharmacol Ther. 2000 Feb;85(2):77-85
10722121
Mov Disord. 1999 Jul;14(4):572-84
10435493
Clin Neuropharmacol. 2006 May-Jun;29(3):148-53
16772814
Mov Disord. 2007 Jun 15;22(8):1145-9
17661426
Trends Neurosci. 2000 Oct;23(10 Suppl):S86-91
11052225
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S68-71
20083012
Mov Disord. 2005 Sep;20(9):1205-9
15954135
Parkinsonism Relat Disord. 2005 Sep;11(6):393-8
15993640
Mov Disord. 2004 Apr;19(4):397-405
15077237
Clin Neuropharmacol. 1993 Oct;16(5):418-27
8106150
Neuron. 1999 Dec;24(4):1003-16
10624962
Mov Disord. 2006 Nov;21(11):1998-2001
16941461
Mov Disord. 2007 Jul 30;22(10):1379-1389
17427940
Mov Disord. 2008;23 Suppl 3:S599-612
18781681
Clin Pharmacokinet. 2004;43(11):707-24
15301575
Clin Neuropharmacol. 2003 May-Jun;26(3):146-50
12782917